Tamarai Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 12-12-2024
- Paid Up Capital ₹ 0.10 M
as on 12-12-2024
- Company Age 18 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.89 M
as on 12-12-2024
- Revenue -7.64%
(FY 2020)
- Profit -13.16%
(FY 2020)
- Ebitda 92.95%
(FY 2020)
- Net Worth 3.24%
(FY 2020)
- Total Assets -6.18%
(FY 2020)
About Tamarai Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.89 M.
Perumal Ganeshkumar and Ganesh Devi serve as directors at the Company.
- CIN/LLPIN
U51397TZ2006PTC013187
- Company No.
013187
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Nov 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- Location
Coimbatore, Tamil Nadu, India
- Telephone
- Email Address
- Social Media-
What products or services does Tamarai Drugs Private Limited offer?
Tamarai Drugs Private Limited offers a wide range of products and services, including Surgical & ICU Equipments, Patient Monitoring System, Digestive System Drugs & Medicines, Antacid Drugs.
Who are the key members and board of directors at Tamarai Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Perumal Ganeshkumar  | Director | 28-Feb-2009 | Current |
| Ganesh Devi | Director | 15-Sep-2016 | Current |
Financial Performance of Tamarai Drugs.
Tamarai Drugs Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 7.64% decrease. The company also saw a substantial fall in profitability, with a 13.16% decrease in profit. The company's net worth moved up by a moderate rise of 3.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tamarai Drugs?
In 2018, Tamarai Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹4.89 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.49 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Oct 2021 | Others | ₹4.89 M | Open |
How Many Employees Work at Tamarai Drugs?
Unlock and access historical data on people associated with Tamarai Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tamarai Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tamarai Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
